BioCina launches manufacturing program for Patrys’ injectable delirium therapy

BioCina advances delirium therapy manufacturing

Image: BioChinaBioCina has begun a comprehensive manufacturing program to support the development of a new injectable therapy targeting delirium in intensive care settings. The Perth-based contract development and manufacturing organisation (CDMO) announced it has initiated a Chemistry, Manufacturing and Controls (CMC) program for RLS-2201, a proprietary injectable formulation of Quetiapine being developed by Patrys Ltd. Production of the reform…

BioCina launches manufacturing program for Patrys’ injectable delirium therapy

BioCina Pty Ltd, a global Contract Development and Manufacturing Organisation (CDMO), has launched a comprehensive manufacturing program for RLS-2201, a proprietary injectable formulation of Quetiapine being developed by Patrys Ltd (ASX: PAB) for the acute treatment of delirium in intensive care.